IDH2 and acute myeloid leukemia: It is important to note that the venetoclax doses used in the small IDH-mutated AML studies described above were frequently higher (ranging from 400 mg to 1200 mg daily) than the FDA-approved CLL dose of 400 mg daily [102,103,122].